

Design, Synthesis of Spirooxindole-pyrrolidines Embedded with Indole and Pyridine Heterocycles by Multicomponent Reaction: Anticancer and In Silico Studies

Sivakalai Mayakrishnan, ^a Devarajan Kathirvelan, ^b Yuvaraj Arun, ^a Krishnan Saranraj, ^c Chandrasekaran Balachandran, ^d Shin Aoki, ^d Pannerselvam Yuvaraj, ^e Narayanan Uma Maheswarai, ^{*a}

(a) Organic & Bioorganic Chemistry, CSIR-Central Leather Research Institute, Adyar, Chennai 600020, India, Email: umamaheswari@clri.res.in

(b) Department of Chemistry, Indian Institute of Technology Hyderabad, India

(c) Department of Physical Chemistry, Madurai Kamaraj University, Madurai 625 021, India

(d) Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510, Japan

(e) CSIR-North East Institute of Science & Technology (NEIST), Branch Laboratory, Imphal- 795004, Manipur, India

Supporting Information


Contents

1. Materials and Methods.....	3
2. General experimental procedure for the synthesis of spirooxindole-pyrrolidine derivatives (4a-m).....	3
3. Spectral data for synthesised compound (4a-m)	4
4. General procedure for the synthesis of spirooxindole-pyrrolidine derivatives (4n-u).....	11
5. Spectral data for synthesised compound (4n-u)	12
6. General procedure for synthesis of spirooxindole-pyrrolidine derivatives (4v-x)	17
7. Spectral data for synthesized compound (4v-x)	17
8. X-ray crystallographic data of compound 4f.....	20
9. X-ray crystallographic data of compound 4f.....	21
10. ¹H and ¹³C NMR spectra of synthesised compounds (4a-x)	22
11. Molecular docking studies of compound (4a-x) with Bcl2-receptor(4IEH).....	46
12. Molecular docking studies of compound (4a-x) with ALK-receptor(2XP2).....	58
13. Binding Energy Data from Docking Analysis	71
14. ¹⁹F NMR of compound 4f, 4m and 4p	72

1. Materials and Methods

All the chemicals were purchased from commercial sources, especially from Sigma Aldrich and used without any further purification. The synthesis of spirooxindole-pyrrolidine derivatives was carried out using 1,3 dipolar cycloaddition reaction of various isatin derivatives with dipolarophile and sarcosine, L-Proline or thioproline in ethanol under reflux for about 2.5 to 3 h to afford the desired product. The synthetic strategy to obtain these derivatives has been provided in the schemes. The compound characterised for ^1H NMR and ^{13}C NMR spectra were performed 400 MHz and 100 MHz Bruker spectrometer. The Chemical shifts values in parts per million (ppm) with TMS (0 ppm) and CDCl_3 or $\text{DMSO}-d_6$ as standards for ^1H NMR and ^{13}C NMR spectra. Infrared spectroscopy of all the compounds was measured using Bruker-Alpha-p instrument. All the TLC analyses were carried out using Merck silica gel 60 F254 plates. Column chromatography was performed on Merck silica gel (100–200 mesh). IR spectra were measured using a Bruker FT IR spectrometer.


2. General experimental procedure for the synthesis of spirooxindole-pyrrolidine derivatives (4a-m)



In an oven-dried 50 ml round bottom flask fixed with a reflux condenser were added a mixture of substituted isatin **1a-m** (1.0 mmol), sarcosine **2a** (1.0 mmol) and (E)-2-(1H-indole-3-carbonyl)-3-(pyridin-3-yl)acrylonitrile **3a** (1.0 mmol) in ethanol (5.0 mL) for reflux 2.5 to 3 hours. After completion of the reaction, as evidenced by TLC analysis, the reaction mixture was poured into ice water, the resulting solid was filtered off, and the solid was washed with cold ethanol to afford pure spirooxindole-pyrrolidine derivatives in nature of colourless solid (**4a-m**).


3. Spectral data for synthesised compound (4a-m)

3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4a)



The compound is prepared according to the general reaction procedure. Colourless solid; Yield 96 %; mp 232 °C; FT-IR (cm⁻¹) Neat; 548, 623, 748, 798, 935, 1025, 1158, 1238, 1327, 1429, 1511, 1625, 1712, 2864, 3216; ¹H NMR (400 MHz, DMSO-d₆) δ 11.91 (s, 1H), 10.45 (s, 1H), 8.68 (d, *J* = 2.3 Hz, 1H), 8.50 (dd, *J* = 4.8, 1.6 Hz, 1H), 8.17 (dt, *J* = 5.2, 3.2 Hz, 1H), 7.98 (dt, *J* = 8.1, 2.0 Hz, 1H), 7.84 (dd, *J* = 7.6, 1.3 Hz, 1H), 7.45 – 7.33 (m, 3H), 7.27 (td, *J* = 7.6, 1.2 Hz, 1H), 7.23 – 7.19 (m, 2H), 6.79 (s, 1H), 6.61 (d, *J* = 7.6 Hz, 1H), 5.50 (t, *J* = 8.6 Hz, 1H), 3.70 (d, *J* = 9.4 Hz, 2H), 2.17 (s, 3H); ¹³C NMR (100 MHz, DMSO-d₆) δ 179.81, 174.31, 151.12, 149.43, 143.03, 137.27, 135.99, 134.25, 133.88, 131.43, 126.85, 126.59, 126.57, 125.69, 124.26, 123.91, 123.35, 122.13, 119.33, 112.87, 112.81, 112.16, 76.78, 66.26, 56.01, 43.04, 40.61, 40.40, 40.20, 39.99, 39.78, 39.57, 39.36, 35.58 ppm; ESI MS *m/z* = 448 [M+H]⁺; Anal. Calculated for C₂₇H₂₁N₅: C, 62.08; H, 3.82; N, 12.07. Found: C, 69.12; H, 3.81; N, 12.01.


3'-(1H-indole-3-carbonyl)-1,1'-dimethyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4b)



The compound is prepared according to the general procedure. Colourless solid; Yield 90 %; mp 226 °C; FT-IR (cm⁻¹) Neat; 545, 589, 641, 744, 794, 937, 1008, 1049, 1097, 1158, 1244, 1352, 1438, 1497, 1617, 1700, 2853, 3056, 3033, 3480; ¹H NMR (400 MHz, DMSO-d₆) δ 11.88 (s, 1H), 8.67 (d, *J* = 1.9 Hz, 1H), 8.52 (dd, *J* = 4.7, 1.4 Hz, 1H), 8.11 (dd, *J* = 6.1, 3.0 Hz, 1H), 8.00 (d, *J* = 8.0 Hz, 1H), 7.86 (d, *J* = 7.3 Hz, 1H), 7.49 – 7.41 (m, 2H), 7.39 – 7.29 (m, 2H), 7.21 (dq, *J* = 7.0, 3.9 Hz, 2H), 6.83 – 6.74 (m, 2H), 5.47 (t, *J* = 8.6 Hz, 1H), 3.80 – 3.67 (m, 2H), 2.69 (s,


3H), 2.13 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.59, 172.42, 150.62, 148.85, 144.85, 136.75, 135.35, 133.64, 133.57, 131.12, 125.91, 124.91, 123.61, 123.57, 123.38, 122.67, 122.63, 121.33, 118.79, 112.34, 112.24, 108.92, 76.53, 65.99, 56.02, 42.38, 35.11, 25.55 ppm; ESI MS m/z = 462 $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{28}\text{H}_{23}\text{N}_5\text{O}_2$: C, 72.87; H, 5.02; N, 15.17. Found: C, 72.91; H, 5.07; N, 15.13.

1-ethyl-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4c)



The compound is prepared according to the general procedure. Colourless solid; Yield 89 %; mp 240 °C; FT-IR (cm^{-1}) Neat; 535, 642, 717, 1160, 1358, 1448, 1603, 1703, 2861, 2973, 3094; ^1H NMR (400 MHz, DMSO) δ 11.73 (s, 1H), 8.70 (s, 1H), 8.55 – 8.47 (m, 1H), 8.17 – 8.10 (m, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 7.3 Hz, 1H), 7.50 – 7.41 (m, 2H), 7.34 (t, J = 7.2 Hz, 2H), 7.24 – 7.14 (m, 2H), 6.82 (d, J = 7.8 Hz, 1H), 6.76 (s, 1H), 5.51 (t, J = 8.5 Hz, 1H), 3.73 (d, J = 8.6 Hz, 2H), 3.48 (dd, J = 14.1, 7.2 Hz, 1H), 3.18 (dt, J = 14.4, 7.2 Hz, 1H), 2.13 (s, 3H), 0.42 (t, J = 7.1 Hz, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.03, 171.80, 150.53, 148.71, 143.83, 136.67, 135.29, 133.74, 133.66, 131.11, 126.04, 125.08, 123.69, 123.48, 123.28, 122.60, 122.44, 121.47, 118.74, 112.26, 112.09, 108.93, 76.20, 65.68, 55.51, 42.13, 35.03, 33.55, 11.43 ppm; ESI MS m/z = 476 $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{29}\text{H}_{25}\text{N}_5\text{O}_2$: C, 73.25; H, 5.30; N, 14.73. Found: C, 73.21; H, 5.59; N, 14.75.


1-allyl-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4d)



The compound is prepared according to the general procedure. Colourless solid; Yield 86 %; mp 236 °C; FT-IR (cm^{-1}) Neat; 641, 740, 788, 33, 1052, 1100, 1158, 1234, 1353, 1443, 1604, 1638, 1705, 2684, 2862, 3049; ^1H NMR (400 MHz, DMSO- d_6)


δ 11.91 (s, 1H), 8.68 (d, J = 2.2 Hz, 1H), 8.51 (dd, J = 4.8, 1.6 Hz, 1H), 8.13 (dd, J = 6.3, 2.9 Hz, 1H), 8.00 (dt, J = 8.1, 2.0 Hz, 1H), 7.93 – 7.86 (m, 1H), 7.49 – 7.41 (m, 3H), 7.34 (t, J = 7.5 Hz, 2H), 7.24 – 7.18 (m, 2H), 6.79 (s, 1H), 6.72 (d, J = 7.8 Hz, 1H), 5.51 (dd, J = 9.9, 7.2 Hz, 1H), 5.19 – 5.03 (m, 1H), 4.66 (dd, J = 17.2, 1.7 Hz, 1H), 4.52 – 4.42 (m, 1H), 3.88 – 3.68 (m, 4H), 2.14 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.25, 172.05, 150.65, 148.87, 144.03, 136.82, 135.47, 133.91, 133.64, 131.13, 130.93, 126.19, 125.10, 123.66, 123.43, 122.77, 121.61, 118.88, 116.68, 112.41, 112.22, 109.73, 76.36, 65.85, 55.53, 42.41, 41.24, 35.14 ppm; ESI MS m/z = 488 $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{30}\text{H}_{25}\text{N}_5\text{O}_2$: C, 73.90; H, 5.17; N, 14.36. Found: C, 73.87; H, 5.19; N, 14.39.

1-benzyl-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4e)




The compound is prepared according to the general procedure. Colourless solid; Yield 87 %; mp 218 °C; FT-IR (cm^{-1}) Neat; 552,630, 701, 739, 787, 858, 921, 1001, 1101, 1171, 1233, 1346, 1444, 1624, 1705, 2235, 2661, 2739, 2799, 2491, 3049; ^1H NMR (400 MHz, DMSO- d_6) δ 12.03 (s, 1H), 8.73 (s, 1H), 8.51 (d, J = 3.8 Hz, 1H), 8.09 (s, 1H), 7.97 (dd, J = 23.5, 7.9 Hz, 2H), 7.43 (dd, J = 12.4, 7.8 Hz, 3H), 7.25 – 7.03 (m, 8H), 6.94 (t, J = 7.5 Hz, 1H), 6.64 (d, J = 7.8 Hz, 1H), 5.45 (t, J = 8.7 Hz, 1H), 4.99 (d, J = 15.8 Hz, 1H), 4.70 (d, J = 15.7 Hz, 1H), 3.85 (t, J = 8.7 Hz, 1H), 3.53 (t, J = 9.6 Hz, 1H), 2.01 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.41, 172.75, 150.71, 148.76, 141.93, 137.02, 135.70, 135.60, 133.96, 133.16, 129.93, 128.55, 127.44, 126.98, 126.04, 123.54, 123.24, 122.58, 122.27, 121.34, 118.24, 112.74, 112.38, 109.57, 76.65, 64.58, 55.38, 44.08, 43.10, 34.95 ppm; ESI MS m/z = 538 $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{34}\text{H}_{27}\text{N}_5\text{O}_2$: C, 75.96; H, 5.06; N, 13.03. Found: C, 75.92; H, 5.10; N, 14.13.06.

5-fluoro-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4f)



The compound is prepared according to the general procedure. Colourless solid; Yield 84 %; mp 248 °C; FT-IR (cm⁻¹) Neat; 584, 636, 724, 795, 837, 953, 1020, 1155, 1245, 1038, 1361, 1438, 1485, 1621, 1701, 2797, 2869, 2937, 3262, 3742, 3841; ¹H NMR (400 MHz, DMSO-d₆) δ 11.94 (s, 1H), 10.52 (s, 1H), 8.67 (d, *J* = 2.1 Hz, 1H), 8.52 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.20 – 8.15 (m, 1H), 7.99 (dd, *J* = 6.3, 1.8 Hz, 1H), 7.59 (dd, *J* = 8.3, 2.7 Hz, 1H), 7.48 – 7.37 (m, 2H), 7.24 (ddd, *J* = 9.2, 7.6, 2.8 Hz, 3H), 6.94 (s, 1H), 6.64 (dd, *J* = 8.6, 4.4 Hz, 1H), 5.48 (dd, *J* = 9.9, 7.2 Hz, 1H), 3.76 – 3.66 (m, 2H), 2.18 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-d₆) δ 179.27, 174.10, 159.15, 156.78, 150.63, 148.90, 139.87, 139.85, 136.78, 135.49, 133.88, 133.46, 126.12, 126.05, 125.97, 123.75, 123.41, 122.84, 121.67, 118.84, 117.72, 117.49, 113.02, 112.77, 112.37, 112.35, 111.24, 111.16, 76.59, 76.57, 65.68, 56.04, 42.46, 35.13 ppm; ESI MS *m/z* = 466 [M+H]⁺; Anal. Calculated for C₂₇H₂₀FN₅O₂: C, 69.67; H, 4.33; N, 15.05. Found: C, 69.69; H, 4.35; N, 14.15.01.


5-chloro-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4g)



The compound is prepared according to the general procedure. Colourless solid; Yield 90 %; mp 240 °C; FT-IR (cm⁻¹) Neat; 554, 637, 717, 799, 878, 945, 1011, 1054, 1138, 1187, 1204, 1287, 1345, 1413, 1465, 1516, 1625, 1705, 2676, 2799, 2955, 3742; ¹H NMR (400 MHz, DMSO-d₆) δ 12.03 (s, 1H), 10.64 (s, 1H), 8.65 (d, *J* = 2.1 Hz, 1H), 8.52 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.16 (dt, *J* = 7.2, 3.6 Hz, 1H), 7.99 (dt, *J* = 7.9, 1.6 Hz, 1H), 7.77 (d, *J* = 2.2 Hz, 1H), 7.47 – 7.42 (m, 2H), 7.39 (dd, *J* = 6.1, 2.9 Hz, 1H), 7.22 (dq, *J* = 7.0, 3.9 Hz, 2H), 6.90 (s, 1H), 6.66 (d, *J* = 8.3


Hz, 1H), 5.43 (dd, $J = 10.1, 7.0$ Hz, 1H), 3.70 (p, $J = 9.4$ Hz, 2H), 2.17 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.35, 173.84, 150.66, 148.97, 142.57, 136.80, 135.53, 133.79, 133.41, 130.96, 126.39, 126.12, 126.10, 125.23, 123.80, 123.45, 122.89, 121.67, 118.86, 112.40, 112.34, 111.69, 76.31, 65.80, 55.55, 42.58, 35.12. ppm; ESI MS $m/z = 482$ $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{27}\text{H}_{20}\text{ClN}_5\text{O}_2$: C, 67.29; H, 4.18; N, 14.53. Found: C, 67.31; H, 4.16; N, 14.14.50.

5-bromo-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4h)



The compound is prepared according to the general procedure. Colourless solid; Yield 88 %; mp 260 °C; FT-IR (cm^{-1}) Neat; 633, 732, 796, 934, 1052, 1150, 1237, 1312, 1360, 1428, 1513, 1618, 1723, 2671, 2800, 3294; ^1H NMR (400 MHz, DMSO- d_6) δ 12.10 (s, 1H), 10.94 (s, 1H), 8.60 (d, $J = 73.6$ Hz, 2H), 8.21 – 7.87 (m, 3H), 7.54 – 7.08 (m, 6H), 6.51 (d, $J = 7.9$ Hz, 1H), 5.32 (s, 1H), 3.79 (t, $J = 8.1$ Hz, 1H), 3.52 (d, $J = 8.8$ Hz, 1H), 2.07 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.71, 173.88, 150.56, 148.71, 140.82, 136.93, 135.68, 133.60, 133.00, 132.64, 129.34, 125.98, 125.80, 123.55, 123.22, 122.62, 121.24, 118.12, 113.67, 112.90, 112.26, 111.65, 76.86, 64.48, 55.25, 44.11, 34.88 ppm; ESI MS $m/z = 526$ $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{27}\text{H}_{20}\text{BrN}_5\text{O}_2$: C, 61.61; H, 3.83; N, 13.30. Found: C, 61.64; H, 3.80; N, 13.32.


3'-(1H-indole-3-carbonyl)-5-iodo-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4i)



The compound is prepared according to the general procedure. Colourless solid; Yield 80 %; mp 228 °C; FT-IR (cm^{-1}) Neat; 549, 633, 705, 745, 803, 875, 944, 1031, 1135, 1233, 1312, 1423, 1469, 1515, 1643, 1723, 2318, 2857, 3131, 3360, 3742, 3840; ^1H NMR (400 MHz, DMSO- d_6) δ 12.09 (s, 1H), 10.95 (s, 1H), 8.73 – 8.67 (m, 1H), 8.54 – 8.47 (m, 1H), 8.10 (d, $J = 3.4$ Hz, 1H),


8.04 – 7.99 (m, 1H), 7.94 (dt, $J = 8.1, 2.0$ Hz, 1H), 7.49 – 7.41 (m, 3H), 7.33 (dd, $J = 8.1, 1.7$ Hz, 1H), 7.25 – 7.15 (m, 3H), 6.41 (d, $J = 8.2$ Hz, 1H), 5.30 (t, $J = 8.7$ Hz, 1H), 3.80 (t, $J = 9.1$ Hz, 1H), 3.50 (t, $J = 9.2$ Hz, 1H), 2.07 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.82, 173.80, 150.55, 148.74, 141.29, 138.45, 136.99, 135.70, 134.78, 133.53, 133.05, 126.13, 126.01, 123.58, 123.29, 122.67, 121.36, 118.29, 113.00, 112.28, 112.08, 84.86, 76.75, 64.43, 55.34, 44.18, 34.92 ppm; ESI MS $m/z = 574$ $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{27}\text{H}_{20}\text{N}_5\text{O}_2$: C, 56.56; H, 3.52; N, 12.21. Found: C, 56.59; H, 3.49; N, 12.25.

3'-(1H-indole-3-carbonyl)-1'-methyl-5-nitro-2-oxo-4'-(pyridin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4j)




The compound is prepared according to the general procedure. Colourless solid; Yield 78 %; mp 240 °C; FT-IR (cm^{-1}) Neat; 639, 743, 798, 1093, 1158, 1241, 1338, 1433, 1519, 1635, 1735, 2857, 2929, 3257, 3613, 3742, 3840; ^1H NMR (400 MHz, DMSO- d_6) δ 12.11 (s, 1H), 11.53 (s, 1H), 8.68 (s, 1H), 8.52 (d, $J = 3.6$ Hz, 1H), 8.11 (d, $J = 2.9$ Hz, 1H), 7.96 – 7.84 (m, 4H), 7.47 – 7.36 (m, 2H), 7.20 – 7.14 (m, 1H), 7.12 – 7.06 (m, 1H), 6.72 (d, $J = 8.6$ Hz, 1H), 5.31 (t, $J = 8.7$ Hz, 1H), 3.86 (t, $J = 9.4$ Hz, 1H), 3.59 (t, $J = 8.9$ Hz, 1H), 2.13 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.87, 174.98, 150.44, 148.93, 147.96, 142.08, 136.99, 135.69, 133.27, 132.70, 126.92, 125.89, 125.13, 123.77, 123.45, 122.75, 121.97, 120.96, 118.14, 113.22, 112.40, 110.16, 76.50, 64.71, 55.39, 44.47, 34.94 ppm; ESI MS $m/z = 493$ $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{27}\text{H}_{20}\text{N}_6\text{O}_4$: C, 65.85; H, 4.09; N, 17.06. Found: C, 65.81; H, 4.11; N, 17.10.

**1-ethyl-3'-(1H-indole-3-carbonyl)-1'-methyl-5-nitro-2-oxo-4'-(pyridin-3-yl)spiro
[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4k)**



The compound is prepared according to the general procedure. Colourless solid; Yield 80 %; mp 248 °C; FT-IR (cm⁻¹) Neat; 631, 708, 745, 804, 952, 1020, 1074, 1150, 1231, 1328, 1424, 1505, 1603, 1725, 2869, 3203; ¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (s, 1H), 8.71 – 8.67 (m, 1H), 8.55 – 8.51 (m, 1H), 8.03 (s, 1H), 8.00 – 7.92 (m, 3H), 7.84 (d, *J* = 7.9 Hz, 1H), 7.48 – 7.37 (m, 2H), 7.16 (t, *J* = 7.5 Hz, 1H), 7.08 (t, *J* = 7.5 Hz, 1H), 7.02 (d, *J* = 8.7 Hz, 1H), 5.33 (t, *J* = 8.7 Hz, 1H), 3.88 (t, *J* = 9.4 Hz, 1H), 3.75 (dp, *J* = 14.2, 7.2 Hz, 3H), 3.62 (d, *J* = 8.9 Hz, 1H), 2.09 (s, 3H), 1.06 (t, *J* = 7.1 Hz, 3H) ppm; ¹³C NMR (100 MHz, DMSO-d₆) δ 180.65, 172.92, 150.42, 148.91, 147.90, 142.39, 136.93, 135.66, 133.12, 132.58, 126.86, 125.78, 124.66, 123.72, 123.40, 122.66, 121.61, 120.79, 117.87, 113.21, 112.39, 109.12, 75.90, 64.78, 55.42, 44.41, 35.12, 34.82, 12.18 ppm; ESI MS *m/z* = 521 [M+H]⁺; Anal. Calculated for C₂₉H₂₄N₆O₄: C, 66.91; H, 4.65; N, 16.14. Found: C, 65.88; H, 4.67; N, 16.11.


**1-benzyl-5-bromo-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)spiro
[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4l)**



The compound is prepared according to the general procedure. Colourless solid; Yield 85 %; mp 210 °C; FT-IR (cm⁻¹) Neat; 641, 709, 748, 803, 1074, 1157, 1233, 1331, 1431, 1505, 1638, 1730, 3198; ¹H NMR (400 MHz, DMSO-d₆) δ 12.04 (s, 1H), 8.62 (d, *J* = 80.5 Hz, 2H), 8.04 (d, *J* = 47.9 Hz, 3H), 7.50 (d, *J* = 38.2 Hz, 3H), 7.17 (t, *J* = 23.7 Hz, 8H), 6.59 (d, *J* = 8.4 Hz, 1H), 5.39 (d, *J* = 9.3 Hz, 1H), 4.84 (dd, *J* = 115.9, 15.9 Hz, 2H), 4.04 – 3.48 (m, 2H), 2.04 (s, 3H) ppm; ¹³C NMR (101 MHz, DMSO-d₆) δ 180.34, 172.35, 150.62, 148.78, 141.21, 136.98, 135.74, 135.23, 133.80, 132.90, 132.72, 129.36, 128.60, 127.54, 126.96, 125.97, 124.92, 123.66, 123.26, 122.73, 121.30, 118.03, 114.79,


112.91, 112.43, 111.40, 76.64, 64.59, 55.28, 44.17, 43.16, 34.96 ppm; ESI MS m/z = 616 $[M+H]^+$; Anal. Calculated for $C_{34}H_{26}BrN_5O_2$: C, 66.24; H, 4.29; N, 11.36. Found: C, 66.26; H, 4.67; N, 11.33.

3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(pyridin-3-yl)-5-(trifluoromethoxy)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4m)



The compound is prepared according to the general procedure. Colourless solid; Yield 78 %; mp 218 °C; FT-IR (cm^{-1}) Neat; 556, 630, 718, 791, 1184, 1233, 1427, 1484, 1635, 1713, 3287; 1H NMR (400 MHz, $DMSO-d_6$) δ 11.99 (s, 1H), 10.70 (s, 1H), 8.65 (d, J = 2.2 Hz, 1H), 8.52 (dd, J = 4.8, 1.6 Hz, 1H), 8.17 (dp, J = 7.2, 4.1, 3.7 Hz, 1H), 8.00 (dt, J = 8.1, 2.0 Hz, 1H), 7.74 (dd, J = 2.6, 1.2 Hz, 1H), 7.45 (dd, J = 8.0, 4.8 Hz, 1H), 7.42 – 7.37 (m, 2H), 7.23 (dd, J = 6.1, 3.1 Hz, 2H), 6.91 (d, J = 3.4 Hz, 1H), 6.72 (d, J = 8.5 Hz, 1H), 5.45 (dd, J = 10.3, 6.9 Hz, 1H), 3.78 – 3.66 (m, 2H), 2.18 (s, 3H) ppm; ^{13}C NMR (100 MHz, $DMSO-d_6$) δ 179.31, 174.11, 150.65, 148.96, 142.73, 136.77, 135.56, 133.55, 133.25, 126.06, 125.89, 124.35, 123.79, 123.41, 122.89, 121.67, 118.77, 118.65, 112.44, 112.39, 111.18, 76.29, 65.79, 55.44, 42.55, 35.05 ppm; ESI MS m/z = 532 $[M+H]^+$; Anal. Calculated for $C_{28}H_{20}F_3N_5O_3$: C, 63.28; H, 3.79; N, 13.18. Found: C, 63.25; H, 3.83; N, 13.15.


4. General procedure for the synthesis of spirooxindole-pyrrolidine derivatives (4n-u)



In an oven-dried 50 ml round bottom flask fixed with a reflux condenser were added mixture of substituted a mixture of substituted isatin **1** (1.0 mmol), L-proline **2b** or thioproline **2c** (1.0 mmol) and (E)-2-(1H-indole-3-carbonyl)-3-(quinolin-3-yl)acrylonitrile **3a** (1.0 mmol) in ethanol (5.0 mL) were refluxed for 2.5 to 3 hours. After completion of the reaction, as evidenced by TLC analysis, the reaction mixture was poured into ice water, the resulting solid was filtered off, and the solid was washed with cold ethanol to afford pure spirooxindole-pyrrolidine compounds in nature of colourless solid (**4n-u**).


5. Spectral data for synthesised compound (**4n-u**)

2'-(1H-indole-3-carbonyl)-2-oxo-1'-(pyridin-3-yl)-1',2',5',6',7',7a'-hexahydrospiro [indoline-3,3'-pyrrolizine]-2'-carbonitrile (**4n**)




The compound is prepared according to the general procedure. Colourless solid; Yield 85 %; mp 202 °C; FT-IR (cm⁻¹) Neat; 588, 620, 770, 815, 861, 888, 971, 1072, 1122, 1200, 1270, 1315, 1381, 14732, 1543, 1618, 1671, 1738, 1943, 2048, 2098, 2161, 2267, 2528, 2853, 2922; ¹H NMR (400 MHz, DMSO-d₆) δ 11.89 (s, 1H), 10.47 (s, 1H), 8.78 (d, *J* = 2.0 Hz, 1H), 8.49 (dd, *J* = 4.7, 1.4 Hz, 1H), 8.13 (dq, *J* = 7.1, 3.5 Hz, 1H), 8.07 – 8.02 (m, 1H), 7.92 (d, *J* = 6.9 Hz, 1H), 7.41 (dd, *J* = 8.0, 4.8 Hz, 1H), 7.36 – 7.26 (m, 3H), 7.20 (dt, *J* = 6.0, 3.5 Hz, 2H), 6.71 (d, *J* = 3.4 Hz, 1H), 6.53 (d, *J* = 7.3 Hz, 1H), 5.11 (d, *J* = 9.7 Hz, 1H), 4.33 (td, *J* = 9.4, 9.0, 5.6 Hz, 1H), 2.76 – 2.62 (m, 1H), 2.58 – 2.52 (m, 1H), 2.22 – 2.12 (m, 1H), 2.03 – 1.82 (m, 3H) ppm; ¹³C NMR (101 MHz, DMSO-d₆) δ 179.06, 175.05, 151.00, 148.80, 142.57, 136.72, 135.44, 133.79, 131.61, 130.74, 126.75, 126.01, 125.33, 123.61, 123.27, 122.71, 122.07, 121.64, 118.83, 112.37, 112.20, 109.98, 76.46, 69.01, 66.96, 48.30, 47.62, 31.12, 29.03 ppm; ESI MS *m/z* = 474 [M+H]⁺; Anal. Calculated for C₂₉H₂₃N₅O₂: C, 73.56; H, 4.90; N, 14.79. Found: C, 73.58; H, 4.87; N, 14.84.

6'-(1H-indole-3-carbonyl)-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4o)



The compound is prepared according to the general procedure. Colourless solid; Yield 96 %; mp 198 °C; FT-IR (cm⁻¹) Neat; 587, 342, 735, 913, 1121, 1185, 1242, 1324, 1423, 1520, 1648, 1724, 2938, 3186, 3304; ¹H NMR (400 MHz, DMSO-d₆) δ 12.16 (s, 1H), 10.79 (s, 1H), 8.94 (s, 1H), 8.53 (d, *J* = 4.1 Hz, 1H), 8.15 (dd, *J* = 13.9, 5.8 Hz, 2H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.66 (d, *J* = 7.6 Hz, 1H), 7.47 – 7.37 (m, 2H), 7.18 – 7.11 (m, 1H), 7.08 – 7.01 (m, 2H), 6.93 (t, *J* = 7.6 Hz, 1H), 6.45 (d, *J* = 7.6 Hz, 1H), 4.69 (dt, *J* = 16.4, 6.6 Hz, 2H), 3.85 (d, *J* = 10.6 Hz, 1H), 3.32 (s, 1H), 3.20 – 3.13 (m, 1H), 3.06 (dd, *J* = 11.5, 2.6 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-d₆) δ 179.92, 174.92, 151.86, 149.12, 141.82, 137.51, 135.69, 133.73, 130.49, 130.37, 129.52, 125.81, 123.55, 123.11, 122.48, 121.11, 120.93, 120.55, 117.27, 112.46, 112.25, 109.64, 76.00, 69.44, 65.96, 53.44, 50.89, 35.63 ppm; ESI MS *m/z* = 492 [M+H]⁺; Anal. Calculated for C₂₈H₂₁N₅O₂S: C, 68.42; H, 4.31; N, 14.25; S, 6.52. Found: C, 68.39; H, 4.32; N, 14.23; S, 6.54.


5-fluoro-6'-(1H-indole-3-carbonyl)-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4p)



The compound is prepared according to the general procedure. Colourless solid; Yield 88 %; mp 188 °C; FT-IR (cm⁻¹) Neat; 636, 707, 749, 879, 926, 1141, 1194, 1245, 1312, 1364, 1419, 1483, 1578, 1632, 1731, 3069, 3124, 3228; ¹H NMR (400 MHz, DMSO-d₆) δ 12.19 (d, *J* = 2.7 Hz, 1H), 10.81 (s, 1H), 8.97 – 8.93 (m, 1H), 8.55 – 8.50 (m, 1H), 8.16 (dd, *J* = 10.9, 5.8 Hz, 2H), 7.78 (d, *J* = 7.9 Hz, 1H), 7.58 (dd, *J* = 9.2, 2.5 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.19 – 7.13 (m, 1H), 7.08 (t, *J* = 7.5 Hz, 1H), 6.90 (td, *J* = 9.1, 2.5 Hz, 1H), 6.43 (dd, *J* = 8.6, 4.5 Hz, 1H), 4.75 – 4.64 (m, 2H), 3.87 (d, *J* = 10.9 Hz, 1H), 3.38 (d, *J* = 10.8 Hz, 1H), 3.19 – 3.10 (m, 2H) ppm; ¹³C NMR (100 MHz, DMSO-d₆)


δ 179.78, 174.81, 158.05, 151.88, 149.13, 138.15, 137.55, 135.71, 133.86, 130.23, 125.78, 123.64, 123.07, 122.61, 122.25, 122.17, 120.99, 117.38, 117.28, 117.12, 117.05, 112.45, 112.32, 110.38, 110.30, 76.36, 69.35, 65.95, 53.56, 50.72, 35.61 ppm; ESI MS m/z = 510 $[M+H]^+$; Anal. Calculated for $C_{28}H_{20}FN_5O_2S$: C, 66.00; H, 3.96; N, 13.74; S, 6.29 Found: C, 66.02; H, 3.99; N, 13.70; S, 6.32.

5-chloro-6'-(1H-indole-3-carbonyl)-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4q)



The compound is prepared according to the general procedure. Colourless solid; Yield 93 %; mp 240 °C; FT-IR (cm^{-1}) Neat; 552, 628, 747, 814, 882, 922, 1136, 1244, 1315, 1428, 1473, 1518, 1622, 1728, 3042, 3200; 1H NMR (400 MHz, DMSO- d_6) δ 12.21 (s, 1H), 10.93 (s, 1H), 8.95 (d, J = 1.7 Hz, 1H), 8.56 – 8.50 (m, 1H), 8.15 (dd, J = 14.6, 5.7 Hz, 2H), 7.78 (d, J = 7.9 Hz, 1H), 7.71 (d, J = 1.7 Hz, 1H), 7.47 – 7.40 (m, 2H), 7.17 (t, J = 7.6 Hz, 1H), 7.09 (td, J = 6.2, 5.4, 2.7 Hz, 2H), 6.44 (d, J = 8.3 Hz, 1H), 3.88 – 3.83 (m, 2H), 3.19 – 3.13 (m, 2H), 3.08 (dd, J = 10.1, 7.1 Hz, 1H), 2.83 (dd, J = 10.1, 6.6 Hz, 1H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.87, 174.61, 172.43, 151.78, 149.15, 140.83, 137.62, 135.72, 133.73, 130.46, 130.16, 129.38, 125.76, 125.03, 123.66, 123.09, 122.61, 122.46, 120.98, 116.98, 112.53, 112.33, 110.99, 76.22, 69.25, 65.91, 65.00, 53.99, 36.11 ppm; ESI MS m/z = 526 $[M+H]^+$; Anal. Calculated for $C_{28}H_{20}ClN_5O_2S$: C, 63.94; H, 3.83; N, 13.31; S, 6.09. Found: C, 63.97; H, 3.80; N, 13.28; S, 6.05.


5-bromo-6'-(1H-indole-3-carbonyl)-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4r)



The compound is prepared according to the general procedure. Colourless solid; Yield 90 %; mp 226 °C; FT-IR (cm^{-1}) Neat; 628, 745, 816, 1135, 1172, 1241, 1315, 1425, 1471, 1516, 1627, 1725, 3197; 1H NMR (400 MHz, DMSO- d_6) δ 12.25 (s, 1H),


10.96 (s, 1H), 8.98 (d, $J = 2.3$ Hz, 1H), 8.56 (dd, $J = 4.8, 1.6$ Hz, 1H), 8.24 – 8.14 (m, 2H), 7.82 (d, $J = 7.9$ Hz, 1H), 7.74 (d, $J = 2.1$ Hz, 1H), 7.51 – 7.42 (m, 2H), 7.23 – 7.16 (m, 1H), 7.12 (dq, $J = 7.1, 2.9, 2.2$ Hz, 2H), 6.48 (d, $J = 8.3$ Hz, 1H), 3.94 – 3.82 (m, 2H), 3.42 (d, $J = 11.0$ Hz, 1H), 3.19 (t, $J = 4.5$ Hz, 1H), 3.12 (dd, $J = 10.1, 7.1$ Hz, 1H), 2.86 (dd, $J = 10.1, 6.6$ Hz, 1H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.30, 174.04, 171.86, 151.21, 148.57, 140.25, 137.05, 135.15, 133.15, 129.88, 129.59, 128.80, 125.19, 124.46, 123.08, 122.52, 122.03, 121.88, 120.40, 116.41, 111.96, 111.76, 110.41, 75.65, 68.68, 65.34, 64.43, 53.41, 50.26, 35.53 ppm; ESI MS $m/z = 570$ $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{28}\text{H}_{20}\text{BrN}_5\text{O}_2\text{S}$: C, 58.95; H, 3.53; N, 12.28; S, 5.62. Found: C, 58.91; H, 3.50; N, 12.30; S, 5.63.

6'-(1H-indole-3-carbonyl)-5-nitro-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4s)



The compound is prepared according to the general procedure. Colourless solid; Yield 78 %; mp 260 °C; FT-IR (cm^{-1}) Neat; 559, 628, 734, 816, 1138, 1241, 1327, 1418, 1461, 1522, 1634, 1728, 1984, 2188, 2186, 2854, 2918, 3669, 3742, 3845; ^1H NMR (400 MHz, DMSO- d_6) δ 12.27 (s, 1H), 11.51 (s, 1H), 8.93 (d, $J = 2.3$ Hz, 1H), 8.59 – 8.49 (m, 2H), 8.21 – 8.12 (m, 2H), 7.98 (dd, $J = 8.7, 2.3$ Hz, 1H), 7.67 (d, $J = 8.0$ Hz, 1H), 7.50 – 7.40 (m, 2H), 7.16 (ddd, $J = 8.2, 7.1, 1.2$ Hz, 1H), 7.05 (ddd, $J = 8.1, 7.1, 1.0$ Hz, 1H), 6.62 (d, $J = 8.7$ Hz, 1H), 3.88 – 3.83 (m, 2H), 3.49 (d, $J = 11.3$ Hz, 1H), 3.22 – 3.16 (m, 2H), 3.09 (dd, $J = 10.1, 7.1$ Hz, 1H), 2.83 (dd, $J = 10.2, 6.6$ Hz, 1H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.91, 175.43, 172.44, 151.60, 149.32, 148.41, 141.18, 137.69, 135.74, 133.64, 129.88, 127.44, 125.66, 124.96, 123.81, 123.24, 122.76, 121.35, 120.73, 116.71, 112.65, 112.44, 110.18, 76.09, 69.07, 65.93, 65.02, 53.97, 36.11 ppm; ESI MS $m/z = 537$ $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{28}\text{H}_{20}\text{N}_6\text{O}_4\text{S}$: C, 62.68; H, 3.76; N, 15.66; O, 11.93; S, 5.98. Found: C, 62.65; H, 3.72; N, 15.69; S, 5.95.


1-benzyl-6'-(1H-indole-3-carbonyl)-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4t)



4t

The compound is prepared according to the general procedure. Colourless solid; Yield 91 %; mp 190 °C; FT-IR (cm⁻¹) Neat; 549, 631, 684, 742, 820, 874, 961, 1011, 1080, 1131, 1247, 1322, 1367, 1420, 1474, 1520, 1610, 1661, 1715, 3335; ¹H NMR (400 MHz, DMSO-d₆) δ 12.56 (s, 1H), 8.98 (d, *J* = 3.2 Hz, 1H), 8.48 (d, *J* = 4.0 Hz, 1H), 8.39 (s, 1H), 8.08 (dd, *J* = 22.8, 8.0 Hz, 2H), 7.64 (d, *J* = 7.5 Hz, 1H), 7.55 (d, *J* = 7.9 Hz, 1H), 7.30 – 7.13 (m, 8H), 6.67 (t, *J* = 6.9 Hz, 3H), 5.20 (dd, *J* = 9.9, 6.3 Hz, 1H), 4.88 (d, *J* = 16.0 Hz, 1H), 4.66 (s, 1H), 4.55 (d, *J* = 16.0 Hz, 1H), 4.16 (d, *J* = 9.8 Hz, 1H), 3.52 (d, *J* = 9.7 Hz, 1H), 2.89 (dd, *J* = 10.2, 6.3 Hz, 1H), 2.64 (t, *J* = 10.2 Hz, 1H) ppm; ¹³C NMR (100 MHz, DMSO-d₆) δ 181.82, 174.94, 151.28, 149.29, 143.17, 136.89, 136.34, 135.99, 135.43, 130.56, 130.53, 128.90, 128.43, 127.14, 126.46, 126.04, 125.68, 124.16, 123.25, 122.87, 122.76, 121.34, 120.72, 112.61, 111.47, 109.28, 74.13, 73.50, 54.85, 53.53, 52.21, 42.68, 33.28 ppm; ESI MS *m/z* = 582 [M+H]⁺; Anal. Calculated for C₃₅H₂₇N₅O₂S: C, 72.27; H, 4.68; N, 12.04; O, 5.50; S, 5.51. Found: C, 72.30; H, 4.62; N, 12.01; S, 5.53.

5-bromo-1-ethyl-6'-(1H-indole-3-carbonyl)-2-oxo-7'-(pyridin-3-yl)-1',6',7',7a'-tetrahydro-3'H-spiro[indoline-3,5'-pyrrolo[1,2-c]thiazole]-6'-carbonitrile (4u)




4u

The compound is prepared according to the general procedure. Colourless solid; Yield 78 %; mp 204 °C; FT-IR (cm⁻¹) Neat; 553, 638, 743, 806, 874, 924, 1048, 1110, 1177, 1239, 1347, 1435, 1629, 1721, 1983, 2148, 2681, 2847, 3041; ¹H NMR (400 MHz, DMSO-d₆) δ 12.13 (s, 1H), 8.95 (s, 1H), 8.54 (s, 1H), 8.19 – 7.74 (m, 3H), 7.48 – 7.27 (m, 3H), 7.11 (dt, *J* = 30.7, 7.5 Hz, 2H), 6.65 (d, *J* = 8.4 Hz, 1H), 4.82 – 4.58 (m, 2H), 4.12 (dd, *J* = 74.7, 8.8 Hz, 1H), 3.82 (d, *J* = 11.3 Hz, 2H), 3.45 – 3.30 (m, 5H), 1.06 (t, *J* = 6.9 Hz, 3H) ppm; ¹³C NMR (100 MHz, DMSO-d₆) δ 179.80, 172.40, 151.75, 149.18, 141.68, 137.64, 135.68, 133.54,

133.34, 131.90, 130.10, 125.66, 123.69, 123.11, 122.55, 122.35, 120.85, 116.85, 113.41, 112.63, 112.32, 110.46, 75.73, 69.15, 53.80, 50.84, 35.67, 34.89, 18.52, 11.78 ppm; ESI MS m/z = 598 $[M+H]^+$; Anal. Calculated for $C_{30}H_{24}BrN_5O_2S$: C, 60.20; H, 4.04; N, 11.70; S, 5.36. Found: C, 60.22; H, 4.00; N, 11.66; S, 5.33.


6. General procedure for synthesis of spirooxindole-pyrrolidine derivatives (4v-x)



In an oven-dried 50 ml, round bottom flask fixed with a reflux condenser were added a mixture of substituted isatin **1a** (1.00 mmol), sarcosine **2a** (1.00 mmol) and (E)-2-(1H-indole-3-carbonyl)-3-(quinolin-3-yl) acrylonitrile **3b** (1.00 mmol) in ethanol (5.00 mL) for refluxed 2.5 to 3 hours. After completion of the reaction, as evidenced by TLC analysis, the reaction mixture was poured into ice water, and the resulting solid was filtered off. The solid was washed with ethanol to afford pure quinoline appended spirooxindole-pyrrolidine derivative with moderate to good yields (**4v-x**) in nature of colourless solid.

7. Spectral data for synthesized compound (4v-x)


5-fluoro-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(quinolin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4v)



The compound is prepared according to the general procedure. Colourless solid; Yield 90 %; mp 210 °C; FT-IR (cm^{-1}) Neat; 591, 645, 712, 785, 805, 870, 955, 1131, 1188, 1244, 1359, 1420, 1479, 1624, 1725, 3399; 1H NMR (400 MHz, $DMSO-d_6$) δ 11.89 (s, 1H), 10.54 (s, 1H), 8.98 (d, J = 2.2 Hz, 1H), 8.60 (d, J = 2.3 Hz, 1H), 8.24 – 8.17 (m, 1H), 8.09 – 7.98 (m, 2H), 7.77 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.62 (td, J = 8.4, 2.0 Hz, 2H), 7.37 (dt, J


= 6.7, 2.8 Hz, 1H), 7.28 – 7.19 (m, 3H), 6.93 (s, 1H), 6.64 (dd, J = 8.6, 4.3 Hz, 1H), 5.69 (dd, J = 10.4, 6.6 Hz, 1H), 3.89 (dd, J = 9.4, 6.6 Hz, 1H), 3.79 (t, J = 9.9 Hz, 1H), 2.22 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 179.26, 174.03, 159.14, 156.77, 151.81, 146.99, 139.84, 136.13, 135.45, 133.84, 130.96, 129.70, 128.55, 128.23, 127.20, 126.85, 126.10, 125.94, 123.71, 122.80, 121.64, 118.86, 117.73, 117.50, 112.98, 112.73, 112.34, 112.31, 111.24, 111.16, 76.68, 65.98, 55.60, 42.56, 35.16 ppm; ESI MS m/z = 516 $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{31}\text{H}_{22}\text{FN}_5\text{O}_2$: C, 72.22; H, 4.30; N, 13.58. Found: C, 72.19; H, 4.27; N, 13.54.

5-bromo-3'-(1H-indole-3-carbonyl)-1'-methyl-2-oxo-4'-(quinolin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4w)



The compound is prepared according to the general procedure. Colourless solid; Yield 88 %; mp 236 °C; FT-IR (cm^{-1}) Neat; 540, 647, 700, 747, 777, 807, 883, 976, 1145, 1240, 1327, 1425, 1459, 1508, 1616, 1653, 1717, 2852, 3039, 3313; ^1H NMR (400 MHz, DMSO- d_6) δ 12.11 (s, 1H), 10.98 (s, 1H), 9.03 (s, 1H), 8.54 (s, 1H), 8.26 – 7.92 (m, 4H), 7.80 – 7.39 (m, 4H), 7.18 (dt, J = 13.9, 7.4 Hz, 3H), 6.53 (d, J = 8.2 Hz, 1H), 5.56 (t, J = 8.5 Hz, 1H), 3.97 (t, J = 8.8 Hz, 1H), 3.60 (t, J = 9.4 Hz, 1H), 2.11 (s, 3H) ppm; ^{13}C NMR (100 MHz, DMSO- d_6) δ 180.75, 173.83, 151.83, 146.93, 140.84, 136.27, 135.68, 133.66, 132.68, 130.54, 129.60, 129.40, 128.53, 128.17, 127.20, 126.77, 125.99, 125.71, 123.56, 122.64, 121.24, 118.18, 113.72, 112.89, 112.28, 111.69, 76.96, 64.79, 55.38, 44.27, 34.93 ppm; ESI MS m/z = 576 $[\text{M}+\text{H}]^+$; Anal. Calculated for $\text{C}_{31}\text{H}_{22}\text{BrN}_5\text{O}_2$: C, 64.59; H, 3.85; N, 12.15. Found: C, 64.55; H, 3.87; N, 12.17.

3'-(1H-indole-3-carbonyl)-5-iodo-1'-methyl-2-oxo-4'-(quinolin-3-yl)spiro[indoline-3,2'-pyrrolidine]-3'-carbonitrile (4x)



The compound is prepared according to the general procedure. Colourless solid; Yield 75 %; mp 200 °C; FT-IR (cm⁻¹) Neat; 643, 751, 804, 1141, 1237, 1323, 1421, 1465, 1509, 1637, 1717, 3244; ¹H NMR (400 MHz, DMSO-d₆) δ 12.07 (s, 1H), 10.96 (s, 1H), 9.01 (d, *J* = 2.2 Hz, 1H), 8.52 (d, *J* = 2.3 Hz, 1H), 8.11 – 7.99 (m, 4H), 7.76 (ddd, *J* = 8.4, 6.8, 1.4 Hz, 1H), 7.62 (ddd, *J* = 8.1, 6.8, 1.2 Hz, 1H), 7.53 (d, *J* = 1.7 Hz, 1H), 7.44 – 7.39 (m, 1H), 7.34 (dd, *J* = 8.1, 1.7 Hz, 1H), 7.19 (tt, *J* = 7.3, 5.4 Hz, 2H), 6.40 (d, *J* = 8.2 Hz, 1H), 5.51 (t, *J* = 8.6 Hz, 1H), 3.96 (t, *J* = 9.0 Hz, 1H), 3.58 (t, *J* = 9.2 Hz, 1H), 2.10 (s, 3H) ppm; ¹³C NMR (100 MHz, DMSO-d₆) δ 180.86, 173.71, 151.80, 146.92, 141.28, 138.45, 136.26, 135.68, 134.79, 133.53, 130.55, 129.60, 128.54, 128.17, 127.21, 126.78, 126.00, 123.55, 122.63, 121.32, 118.30, 112.97, 112.26, 112.07, 99.47, 84.85, 76.81, 64.70, 55.43, 44.31, 34.92 ppm; ESI MS *m/z* = 624 [M+H]⁺; Anal. Calculated for C₃₁H₂₂IN₅O₂: C, 59.72; H, 3.56; N, 11.23. Found: C, 59.69; H, 3.59; N, 11.20.

8. X-ray crystallographic data of compound 4f






Table 1 Crystal data and structure refinement for compound 4f

Parameters	Compound 4f
Empirical formula	C ₂₇ N ₅ O ₂ F ₁ H ₁₆
Formula weight	465.16
Temperature/K	296.15
Crystal system	orthorhombic
Space group	Pna21
a/Å	16.4758(10)
b/Å	11.0289(8)
c/Å	24.904(2)
$\alpha/^\circ$	90
$\beta/^\circ$	90
$\gamma/^\circ$	90
Volume/Å ³	4525.3(6)
Z	4
$\rho_{\text{calc}}/\text{cm}^3$	1.366
μ/mm^{-1}	0.095
F(000)	1936.0
Crystal size/mm ³	0.3 × 0.25 × 0.2
Radiation	MoK α (λ = 0.71073)
2 θ range for data collection/ $^\circ$	3.27 to 51.066
Index ranges	-19 ≤ h ≤ 19, -13 ≤ k ≤ 13, -30 ≤ l ≤ 30
Reflections collected	51473
Independent reflections	8424 [R _{int} = 0.0459, R _{sigma} = 0.0392]
Data/restraints/parameters	8424/1/633
Goodness-of-fit on F ²	1.124
Final R indexes [$I \geq 2\sigma(I)$]	R ₁ = 0.0508, wR ₂ = 0.1236
Final R indexes [all data]	R ₁ = 0.0841, wR ₂ = 0.1492
Largest diff. peak/hole / e Å ⁻³	0.27/-0.28
Flack parameter	0.1(4)

9. X-ray crystallographic data of compound 4f



CCDC: 2126948

Table 2 Crystal data and structure refinement for compound 4f

Parameters	4o
Empirical formula	C ₂₈ H ₂₁ N ₅ O ₂ S
Formula weight	491.58
Temperature/K	150
Crystal system	monoclinic
Space group	P2 ₁ /c
a/Å	15.6743(8)
b/Å	10.9532(6)
c/Å	17.2489(8)
α/°	90
β/°	104.833(2)
γ/°	90
Volume/Å ³	2862.7(3)
Z	4
ρ _{calc} /cm ³	1.1405
μ/mm ⁻¹	0.144
F(000)	1024.9
Crystal size/mm ³	0.25 × 0.2 × 0.2
Radiation	Mo Kα (λ = 0.71073)
2θ range for data collection/°	2.68 to 58.88
Index ranges	-18 ≤ h ≤ 18, -13 ≤ k ≤ 13, -20 ≤ l ≤ 20
Reflections collected	54763
Independent reflections	7870 [R _{int} = 0.0508, R _{sigma} = 0.0450]
Data/restraints/parameters	7870/0/325
Goodness-of-fit on F ²	1.095
Final R indexes [I ≥ 2σ (I)]	R ₁ = 0.0649, wR ₂ = 0.2050
Final R indexes [all data]	R ₁ = 0.1088, wR ₂ = 0.2487
Largest diff. peak/hole / e Å ⁻³	0.48/-0.67

10. ^1H and ^{13}C NMR spectra of synthesised compounds (4a-x)




Figure SI-1: ^1H NMR spectrum of compound **4a** in DMSO- d_6




Figure SI-2: ^{13}C NMR spectrum of compound **4a** in DMSO- d_6




Figure SI-3: ¹H NMR spectrum of compound **4b** in DMSO-d₆




Figure SI-4: ¹³C NMR spectrum of compound **4b** in DMSO-d₆




Figure SI-5: ^1H NMR spectrum of compound **4c** in DMSO-d_6




Figure SI-6: ^{13}C NMR spectrum of compound **4c** in DMSO-d_6




Figure SI-7: ¹H NMR spectrum of compound **4d** in DMSO-d₆




Figure SI-8: ¹³C NMR spectrum of compound **4d** in DMSO-d₆




Figure SI-9: ¹H NMR spectrum of compound **4e** in DMSO-*d*₆




Figure SI-10: ¹³C NMR spectrum of compound **4e** in DMSO-*d*₆




Figure SI-11: ^1H NMR spectrum of compound **4f** in $\text{DMSO}-d_6$




Figure SI-12: ^{13}C NMR spectrum of compound **4f** in $\text{DMSO}-d_6$




Figure SI-13: ¹H NMR spectrum of compound **4g** in DMSO-d₆




Figure SI-14: ¹³C NMR spectrum of compound **4g** in DMSO-d₆




Figure SI-15: ¹H NMR spectrum of compound **4h** in DMSO-d₆




Figure SI-16: ¹³C NMR spectrum of compound **4h** in DMSO-d₆




Figure SI-17: ¹H NMR spectrum of compound **4i** in DMSO-d₆




Figure SI-18: ¹³C NMR spectrum of compound **4i** in DMSO-d₆




Figure SI-19: ¹H NMR spectrum of compound **4j** in DMSO-d₆




Figure SI-20: ¹³C NMR spectrum of compound **4j** in DMSO-d₆




Figure SI-21: ^1H NMR spectrum of compound **4k** in DMSO-d_6




Figure SI-22: ^{13}C NMR spectrum of compound **4k** in DMSO-d_6




Figure SI-23: ¹H NMR spectrum of compound **4I** in DMSO-d₆




Figure SI-24: ¹³C NMR spectrum of compound **4I** in DMSO-d₆




Figure SI-27: ¹H NMR spectrum of compound **4n** in DMSO-d₆




Figure SI-28: ¹³C NMR spectrum of compound **4n** in DMSO-d₆




Figure SI-29: ^1H NMR spectrum of compound **4o** in DMSO-d_6




Figure SI-30: ^{13}C NMR spectrum of compound **4o** in DMSO-d_6




Figure SI-31: ¹H NMR spectrum of compound **4p** in DMSO-d₆




Figure SI-32: ¹³C NMR spectrum of compound **4p** in DMSO-d₆




Figure SI-33: ^1H NMR spectrum of compound **4q** in $\text{DMSO}-d_6$




Figure SI-34: ^{13}C NMR spectrum of compound **4q** in $\text{DMSO}-d_6$




Figure SI-35: ¹H NMR spectrum of compound 4r in DMSO-d₆




Figure SI-36: ¹³C NMR spectrum of compound 4r in DMSO-d₆




Figure SI-37: ¹H NMR spectrum of compound **4s** in DMSO-d₆




Figure SI-38: ¹³C NMR spectrum of compound **4s** in DMSO-d₆




Figure SI-39: ¹H NMR spectrum of compound **4t** in DMSO-d₆




Figure SI-40: ¹³C NMR spectrum of compound **4t** in DMSO-d₆




Figure SI-41: ¹H NMR spectrum of compound **4u** in DMSO-d₆




Figure SI-42: ¹³C NMR spectrum of compound **4u** in DMSO-d₆




Figure SI-43: ¹H NMR spectrum of compound **4v** in DMSO-d₆




Figure SI-44: ¹³C NMR spectrum of compound **4v** in DMSO-d₆




Figure SI-45: ^1H NMR spectrum of compound **4w** in DMSO-d_6




Figure SI-46: ^{13}C NMR spectrum of compound **4w** in DMSO-d_6




Figure SI-47: ¹H NMR spectrum of compound **4x** in DMSO-d₆




Figure SI-48: ¹³C NMR spectrum of compound **4x** in DMSO-d₆

11. Molecular docking studies of compound (4a-x) with Bcl2-receptor(4IEH)




Figure SI-49: Binding mode of compound **4a** in Bcl2-receptor




Figure SI-50: Binding mode of compound **4b** in Bcl2-receptor




Figure SI-55: Binding mode of compound **4g** in Bcl2-receptor




Figure SI-56: Binding mode of compound **4h** in Bcl2-receptor




Figure SI-57: Binding mode of compound **4i** in Bcl2-receptor






Figure SI-58: Binding mode of compound **4j** in Bcl2-receptor






Figure SI-61: Binding mode of compound **4m** in Bcl2-receptor




Figure SI-62: Binding mode of compound **4n** in Bcl2-receptor




Figure SI-63: Binding mode of compound **4o** in Bcl2-receptor




Figure SI-64: Binding mode of compound **4p** in Bcl2-receptor




Figure SI-65: Binding mode of compound **4q** in Bcl2-receptor




Figure SI-66: Binding mode of compound **4r** in Bcl2-receptor




Figure SI-67: Binding mode of compound **4s** in Bcl2-receptor






Figure SI-68: Binding mode of compound **4t** in Bcl2-receptor






Figure SI-71: Binding mode of compound **4w** in Bcl2-receptor




Figure SI-72: Binding mode of compound **4x** in Bcl2-receptor

Crystallised Ligand Bcl2 receptor




Figure SI-73: Binding mode of compound **crystallised ligand** in Bcl2-receptor

12. Molecular docking studies of compound (4a-x) with ALK-receptor(2XP2)




Figure SI-74: Binding mode of compound **4a** in Alk-receptor




Figure SI-75: Binding mode of compound **4b** in Alk-receptor




Figure SI-76: Binding mode of compound **4c** in Alk-receptor




Figure SI-77: Binding mode of compound **4d** in Alk-receptor




Figure SI-78: Binding mode of compound **4e** in Alk-receptor




Figure SI-79: Binding mode of compound **4f** in Alk-receptor




Figure SI-80: Binding mode of compound **4g** in Alk-receptor




Figure SI-81: Binding mode of compound **4h** in Alk-receptor




Figure SI-82: Binding mode of compound **4i** in Alk-receptor




Figure SI-83: Binding mode of compound **4j** in Alk-receptor






Figure SI-84: Binding mode of compound **4k** in Alk-receptor






Figure SI-89: Binding mode of compound **4p** in Alk-receptor




Figure SI-90: Binding mode of compound **4q** in Alk-receptor




Figure SI-91: Binding mode of compound **4r** in Alk-receptor




Figure SI-92: Binding mode of compound **4s** in Alk-receptor




Figure SI-95: Binding mode of compound **4v** in Alk-receptor




Figure SI-96: Binding mode of compound **4w** in Alk-receptor




Figure SI-97: Binding mode of compound 4x in Alk-receptor




Figure SI-98: Molecular docking interaction of the crystallised ligand (Crizotinib) with the active site amino acids of ALK receptor (2xp2).

13. Binding Energy Data from Docking Analysis

Compound (Ligand)	Binding Energy in Bcl2	Binding Energy in ALK
4a	-8.33	-6.1
4b	-7.57	-6.23
4c	-6.24	-6.93
4d	-7.72	-5.21
4e	-8.09	-5.42
4f	-7.05	-5.88
4g	-7.09	-6.3
4h	-7.68	-5.6
4i	-8.06	-5.8
4j	-7.8	-6.13
4k	-6.69	-6.12
4l	-7.16	-5.88
4m	-6.05	-6.59
4n	-7.84	-6.14
4o	-6.89	-7.14
4p	-6.9	-6.53
4q	-7.14	-6.32
4r	-7.45	-6.09
4s	-7.45	-5.65
4t	-8.91	-6.11
4u	-6.56	-6.16
4v	-8.29	-6.09
4w	-8.14	-6.46
4x	-7.9	-6.34
Crystallized Ligand	-5.92	-6.74

14. ^{19}F NMR of compound 4f, 4m and 4p




Figure SI-99: ^{19}F NMR spectrum of compound 4f




Figure SI-100: ^{19}F NMR spectrum of compound 4m




Figure SI-101: ^{19}F NMR spectrum of compound **4p**




Figure SI-102: ^{19}F NMR spectrum of compound **4v**